Skip to main content

Table 1 Demographic and clinical characteristics of participants

From: The predictive capabilities of a novel cardiovascular magnetic resonance derived marker of cardiopulmonary reserve on established prognostic surrogate markers in patients with pulmonary vascular disease: results of a longitudinal pilot study

 

PAH

High risk

P value

Participants, n

14

6

 

Female (%)

11 (79)

5 (83)

0.98

Age, years

54 ± 14

63 ± 7.6

0.18

BSA, m2

1.79 ± 0.25

1.83 ± 0.17

0.79

PAH aetiology (%)

 Idiopathic

10 (71)

  

 CTD-associated

4 (29)

  

Coexisting conditions (%)

 Diabetes mellitus

2 (14)

0 (0)

<0.05

 Smoker

1 (12)

0 (0)

<0.05

 CTD

5 (36)

5 (83)

<0.05

NYHA functional class (%)

 II

3 (21)

6 (100)

<0.05

 III

11 (79)

0 (0)

<0.05

Therapy, initial/follow-up (%)

 Phosphodiesterase-5 inhibitor

1 (7)/0 (0)

  

 Combination

13 (93)/14 (100)

  

Creatinine, μmol/L

84 ± 21

83 ± 34

0.96

DLCO, %

55 ± 15

58 ± 19

0.76

%FVC/%DLCO

1.41 ± 0.41

1.38 ± 0.27

0.92